• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  

PubMed=8324732
Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., Clarke R.
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Cancer Res. 53:3229-3232(1993)

PubMed=11078910; DOI=10.1016/S0304-3835(00)00579-6
Lilling G., Hacohen H., Nordenberg J., Livnat T., Rotter V., Sidi Y.
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
Cancer Lett. 161:27-34(2000)

PubMed=23868472; DOI=10.1038/ncomms3175; PMCID=PMC3759040
Johansson H.J., Sanchez B.C., Mundt F., Forshed J., Kovacs A., Panizza E., Hultin-Rosenberg L., Lundgren B., Martens U., Mathe G., Yakhini Z., Helou K., Krawiec K., Kanter L., Hjerpe A., Stal O., Linderholm B.K., Lehtio J.
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer.
Nat. Commun. 4:2175.1-2175.10(2013)